Means and Method for Ovarian Cancer Prognosis

A method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of:

• a) evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
• b) comparing said sample value with a predetermined reference value;
• and,
• if said sample value is higher than said reference value,
• c1) concluding that the subject belongs to the first group;
• and,
• if said sample value is lower than or equal to said reference value,
• c2) concluding that the subject belongs to the second group.

A method for determining whether a subject having an ovarian cancer is not in need of a treatment with an ovarian cancer treatment regimen, comprising the steps of:

• a) evaluating an amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount;
• b) comparing the sample value obtained in step a) with a reference value;
• and,
• if said sample value is higher than said reference value,
• c) concluding that said subject is not in need of the treatment with the ovarian cancer treatment regimen.

A non-treatment strategy method for a subject having an ovarian cancer, comprising:

• a) evaluating an amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount;
• b) comparing the sample value obtained in step a) with a reference value;
• and,
• if said sample value is higher than said reference value,
• c) refraining from treating said subject with an ovarian cancer treatment regimen.

A method for treating a subject having an ovarian cancer, comprising:

• a) evaluating an amount of RBM3 protein or RBM3 mRNA present in at least part of a sample from the subject and determining a sample value corresponding to the evaluated amount;
• b) comparing the sample value obtained in step a) with a reference value;
• and,
• if said sample value is equal to or lower than said reference value,
• c) treating said subject with an ovarian cancer treatment regimen.